Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syncom Formulation (India)NSE:SYNCOMF +4.40%93 Interest Coverage is 100.89 as of Jun. 2026, which is 206% above its 10-year median of 32.92. GuruFocus rates NSE:SYNCOMF with a GF Score™ of 93/100 and a GF Value™ of ₹20.42 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 685 Drug Manufacturers companies, Syncom Formulation (India) ranks better than 74.74% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Syncom Formulation (India)'s
Operating Income
for the
three
months ended in Jun. 2026 was ₹247 Mil. Syncom Formulation (India)'s Interest Expense for the
three
months ended in Jun. 2026 was ₹-2 Mil.
Syncom Formulation (India)'s interest coverage for the quarter that ended in Jun. 2026 was 100.89.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Syncom Formulation (India) Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Syncom Formulation (India)'s Interest Coverage or its related term are showing as below:
NSE:SYNCOMF'
s Interest Coverage Range Over the Past 10 Years
Min: 5.16 Med: 32.92 Max: 181.38
Current: 70.6
NSE:SYNCOMF's Interest Coverage is ranked better than 74.74% of 685
companies
in the Drug Manufacturers industry
Industry Median: 13.91
vs NSE:SYNCOMF: 70.60
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Syncom Formulation (India) Interest Coverage Related Terms
Syncom Formulation (India) Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India) Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Interest Coverage distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syncom Formulation (India) (NSE:SYNCOMF) has a Interest Coverage of 100.89 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Syncom Formulation (India) and its competitors. This is 206% above median its historical median of 32.92. Over the past decade, Syncom Formulation (India)'s Interest Coverage has ranged from 5.16 to 181.38. According to the industry distribution chart, Syncom Formulation (India) ranks #173 out of 685 companies in the Drug Manufacturers industry, placing it in the top 25.3%.
Is Syncom Formulation (India)'s Interest Coverage too high?
Syncom Formulation (India)'s current Interest Coverage of 100.89 is 206% above median its 10-year median of 32.92. Over the past 10 years, this metric has ranged from a low of 5.16 to a high of 181.38. The Drug Manufacturers industry median Interest Coverage is 13.91. Syncom Formulation (India)'s value of 100.89 is 625.3% above this industry median. Based on the distribution chart, Syncom Formulation (India) ranks #173 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Syncom Formulation (India) has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #173 out of 685 companies for Interest Coverage. This puts Syncom Formulation (India) in the upper half of its industry. The industry median Interest Coverage is 13.91. Syncom Formulation (India)'s value of 100.89 is 625.3% above this benchmark. Historically, Syncom Formulation (India)'s own Interest Coverage has ranged from 5.16 to 181.38 over the past decade. While the company's 10-year median is 32.92 vs. the industry median of 13.91, Syncom Formulation (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.91, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syncom Formulation (India)'s current Interest Coverage of 100.89 is 625.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Syncom Formulation (India) and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current Interest Coverage is 100.89, which is 206% above median its own 10-year median of 32.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (NSE:SYNCOMF) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹20.42, compared to a current price of ₹16.14 — trading 21% below its estimated fair value. The current Interest Coverage is 100.89, which is 206% above median its 10-year median of 32.92 and 625.3% above the Drug Manufacturers industry median of 13.91. Syncom Formulation (India)'s overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Syncom Formulation (India) (NSE:SYNCOMF), the current Interest Coverage is 100.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syncom Formulation (India) (NSE:SYNCOMF) Overvalued in 2026?
Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued.
The current stock price of ₹16.14 is trading 21% below its estimated GF Value™ of ₹20.42.
GuruFocus considers Syncom Formulation (India) to be Modestly Undervalued.
Key valuation signals for NSE:SYNCOMF:
Interest Coverage: 100.89 (206% above median its 10-year median of 32.92)
GF Value™: ₹20.42 vs. price of ₹16.14 (21% below fair value)
Industry Position: 625.3% above the Drug Manufacturers median (#173 of 685)
No single metric tells the full story. See the NSE:SYNCOMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
93GF Score
Get the complete analysis for NSE:SYNCOMF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNCOMF has been successfully added to your 
